A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology

Autor: Vladimir Lazar, Baolin Zhang, Shai Magidi, Christophe Le Tourneau, Eric Raymond, Michel Ducreux, Catherine Bresson, Jacques Raynaud, Fanny Wunder, Amir Onn, Enriqueta Felip, Josep Tabernero, Gerald Batist, Razelle Kurzrock, Eitan Rubin, Richard L. Schilsky
Přispěvatelé: Institut Català de la Salut, [Lazar V] Worldwide Innovative Network (WIN) Association–WIN Consortium, Villejuif, France. [Zhang B] Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, MA, USA. [Magidi S] Worldwide Innovative Network (WIN) Association–WIN Consortium, Villejuif, France. [Le Tourneau C] Department of Drug Development and Innovation (D3i), Inserm, Research Unit, Paris-Saclay University, Institut Curie, Paris, France. [Raymond E] Oncology Department, Groupe Hospitalier Paris Saint Joseph, Paris, France. [Ducreux M] Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Inserm, Villejuif, France. [Felip E, Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Scientia
Popis: Oncology; Transcriptomics; Tumor biopsies Oncologia; Transcriptòmica; Biòpsies tumorals Oncología; Transcriptómica; Biopsias tumorales Background: The current model of clinical drug development in oncology displays major limitations due to a high attrition rate in patient enrollment in early phase trials and a high failure rate of drugs in phase III studies. Objective: Integrating transcriptomics for selection of patients has the potential to achieve enhanced speed and efficacy of precision oncology trials for any targeted therapies or immunotherapies. Methods: Relative gene expression level in the metastasis and normal organ-matched tissues from the WINTHER database was used to estimate in silico the potential clinical benefit of specific treatments in a variety of metastatic solid tumors. Results: As example, high mRNA expression in tumor tissue compared to analogous normal tissue of c-MET and its ligand HGF correlated in silico with shorter overall survival (OS; p
Databáze: OpenAIRE